Malonic acid (4.024 g, 38.67 mmol), piperidine (7.7 mL) and dry pyridine (54 mL) were added to the mixture of aldehydes B and 2,5-dimethyl-4-nitro-benzaldehyde (6.928 g, 38.67 mmol) and the mixture was heated under reflux for 1 h. The mixture was cooled to r.t., a second equivalent of malonic acid (4.024 g, 38.67 mmol) was added and the mixture was heated under reflux for 1 h. The mixture was again cooled to r.t., a third equivalent of malonic acid (4.024 g, 38.67 mmol) was added and the mixture was heated under reflux for 15 h. The mixture was cooled to r.t. and concentrated under reduced pressure. CH 2 Cl 2 (100 mL) was added and the carboxylate salt of the product was extracted with aqueous NaOH (3 x 100 mL, 2 M). The combined water layers were filtered and acidified to pH<1 by addition of aqueous HCl (35%). The resulting precipitate was filtered under vacuum, washed with aqueous HCl (100 mL, 2M), air-dried and dried under vacuum to give cinnamic acid C and regioisomer 2,5-dimethyl-4-nitrocinnamic acid as an amorphous solid (6.26 g, combined yield 73%, yield of C 55%). Compounds C and 2,5-dimethyl-4-nitrocinnamic acid were obtained in a ratio of 3:1 (M:m): R f [petrol:EtOAc (85:15) 
3-Acetamido-2,5-dimethylcinnamic acid (D)
AcOH (13 mL) was added to the mixture of cinnamic acids C and 2,5-dimethyl-4-nitrocinnamic acid (1.50 g, 6.78 mmol). Raney nickel (approximately 3 mL of slurry) was added and the mixture was stirred under S-5 an H 2 atmosphere for 19 h. Use of an H 2 balloon without evacuating the flask to remove the air prior to adding the balloon avoided reduction of the double bond as well as the nitro group. The mixture was filtered and the catalyst was washed with AcOH (50 mL). The solution was concentrated to approximately 6 mL, Ac 2 O (1.7 mL) was added, and the solution was heated under reflux for 2 h. The mixture was cooled to r.t. and concentrated under reduced pressure. Aqueous HCl (100 mL, 1 M) was added, the mixture was filtered and the solid was washed with aqueous HCl (20 mL, 1 M) and air-dried to give crude acid D and regioisomer 4-acetamido-2,5-dimethylcinnamic acid (1.14 g 
4-(3-Bromopyridin-2-ylamino)-2,5-dimethylbenzoic acid (3)
Bromopyridine 1 (4 g, 14.7 mmol) was dissolved in dry CH 2 Cl 2 (26 mL) and cooled to -78 °C. AlCl 3 (13.7 g, 102.9 mmol) was added portionwise and the mixture was stirred for 5 min. MeOCHCl 2 (4 mL, 44.1 mmol) was added dropwise. The mixture was stirred for 18 h whilst being allowed to warm to r.t.. The mixture was poured cautiously into ice-water (80 mL) and the crude aldehyde 2 was extracted with CH 2 Cl 2 (3 x 200 mL). The combined organic layers were dried (Mg 2 SO 4 ), filtered and concentrated under reduced pressure. The mixture was suspended in a mixture of acetone (80 mL) and water (290 mL). NH 2 SO 3 H (2.07 g, 21.3 mmol) and NaClO 2 (2.13 g, 23.5 mmol) were added and the mixture was stirred for 16 h at r.t.. The crude product was extracted with EtOAc (3 x 200 mL) and the carboxylate salt of the product was extracted from EtOAc with aqueous NaOH (4 x 300 mL, 2 M). The combined NaOH layers were acidified to approximately pH 5 using conc. HCl and the resulting precipitate was filtered, air-dried, and dried under vacuum to give acid 3 (3.14 g, 66% 
6-(3-Bromopyridin-2-ylamino)-5,8-dimethylisoquinolin-1(2H)-one (5)
Polyphosphoric acid (80 g) was heated to 110 °C. Amide 4 (2.00 g, 4.58 mmol) was added portionwise and the mixture stirred for 16 h at 110 °C. The mixture was poured onto ice-water (250 mL) and the crude product was extracted with CHCl 3 (3 x 250 mL). The combined organic layers were dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure. Purification by flash column chromatography, eluting with EtOAc-petrol (10:90), gave lactam 5 (1.10 g, 70%) as an amorphous solid; mp 89-91 °C; R f [petrol:EtOAc (9:1)] 0.21; IR υ max (solid)/cm -1 3425, 3135, 2915, 2855, 1700, 1595, 1555, 1520, 1480, 1450, 1410, 1360, 1250, 1120, 1105 
Chlorination on nitrogen atom
Treatment of compound 5 with PCl 5 in POCl 3 gave N-chloro derivative F (Scheme S3). Chlorination of VG1 under the same conditions gave a low yield of impure N-chlorinated product.
Scheme S3: Chlorination on nitrogen atom.
Experimental method 
Cell biology Experimental methods

Cell culture, transfection and drug treatments
The plasmids pmCMV-Gl (NORM), pmCMV-Gl (TER) and phCMV-MUP (referred to as NORM, TER and MUP) were a kind gift from Lynne Maquat (University of Rochester, New York). HeLa cells were cultured in DMEM High Glucose (4.5 g/L) with 4 mM L-glutamine (PAA) supplemented with 10% foetal bovine serum (Sigma Aldrich or Gibco) and were incubated at 37 °C with 5% CO 2 . Cells were seeded in 6 or 12-well plates at a density of 1-2 x 10 4 cells/cm 2 and incubated for 24 h to allow them to attach to the wells.
For transfection experiments, cells were transfected with the MUP plasmid (0.75 μg for 6-well plates or 0.3 μg for 12-well plates) and either the NORM or TER plasmid (0.75 μg for 6-well plates or 0.3 μg for 12-well plates) using Polyfect Transfection Reagent (Qiagen) using the supplied protocol. For 12-well plates, the standard protocol for 6-well plates was scaled down according to the relative surface area of the plates. Cells were exposed to the transfection medium for 24 h. Compound-containing culture medium was prepared with compound at a final concentration of 0.2-125 μM. A 5 mM stock solution of VG1 or NMDI1 (a kind gift from Jocelyn Méré, CNRS, Montpelier) in DMSO was used to prepare the medium, with the following exceptions: a 40 mM stock solution in DMSO was used to prepare medium containing VG1 at a final concentration of 125 or 25 μM and a 0.4 mM stock solution in DMSO was used to prepare medium containing VG1 at a final concentration of 0.2 μM. The final concentration of DMSO in the medium was adjusted so as to remain constant. Cells were exposed to compound (or DMSO as control) for the indicated times by aspirating untreated culture medium from cells which was replaced with medium containing compound or, as a control, an equivalent volume of DMSO only. Cells were imaged using a Leica DM IL microscope with an AM423X Dino-Eye microscope eyepiece camera. A2780 cis cells were cultured in RPMI1640 supplemented with 10% foetal bovine serum (Sigma Aldrich or Gibco) and treated with 40 μM cisplatin for 36 h prior to lysis and immunoblotting as described below.
RNA analysis
Total RNA was extracted using either Qiagen QIAshredder columns followed by the Qiagen RNeasy kit or by phenol-chloroform extraction using TRI Reagent (Sigma-Aldrich) or TRIzol Reagent (Invitrogen). RNA extraction typically yielded between 1 and 10 μg of RNA (measured using a NanoDrop ND-1000 spectrophotometer). RNA (2 μg per reaction) was reverse transcribed using the Applied Biosystems High Capacity RNA-to-cDNA kit using the supplied protocol. The reaction was incubated at 37 °C for 60 min. The amount of NORM, TER and MUP cDNA was determined by qPCR (where the amount of cDNA serves as a proxy measurement for the amount of mRNA) using a Bio-Rad iCycler thermal cycler with a MyiQ real-time PCR detection system. Master mix containing SYBR Green JumpStart Taq ReadyMix (SigmaAldrich, 12.5 μL), forward and reverse primers (Life Technologies, 0.025 μL of a 100 μM stock solution in water) and water (11.45 μL) were added to the wells of a 96-well qPCR plate. cDNA was diluted with water to a concentration of 100 ng/μL, 1 μL of the 100 ng/μL solution was added to the wells and the plate was sealed with StarSeal polyolefin film (STARLAB). The target cDNA was amplified using a program consisting of 40 cycles, utilising a 95 °C dissociation temperature, 60 °C annealing temperature and 72 °C extension temperature. For β-globin (NORM or TER), qPCR primer sequences were 5'-CACCTGGACAACCTCAAGGGCA-3' and 5'-TGCAGCGGGGGTGAAATCCTTG-3'. For MUP, qPCR primer sequences were 5'-CCAATGCCAATCGCTGCCTCCA-3' and 5'-AGGGATGATGGTGGAGTCCTGGTG-3'. Primers were designed using Primer-BLAST online software. 3 The amounts of NORM and TER mRNA, each expressed as a ratio of the respective amount of MUP mRNA in each sample, were compared in order to determine NMD efficiency. Each sample was analysed in triplicate or quadruplicate. Results were quantified by comparison to a standard curve made by combining cDNA from all samples and analysing S-23 serial dilutions on the qPCR plate. A well containing no template was included to check for contamination and the formation of primer dimers. The data were analysed using Microsoft Excel and Bio-Rad CFX Manager. To determine the size of PCR products to confirm that β-globin mRNA generated as a result of transfection was appropriately spliced, RNA derived from cells either mock transfected, or transfected with either pmCMV-Gl (NORM), or pmCMV-Gl (TER) as above, was harvested and reverse transcribed as above, and subjected to standard PCR where each well contained 200 ng total cDNA, 100 pmol each of forward and reverse primers, together with SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich, 10 μL) in a final volume of 20 µL. β-globin cDNA was amplified using a program consisting of 40 cycles, utilising a 95 °C dissociation temperature, 60 °C annealing temperature and 72 °C extension temperature. DNA electrophoresis was undertaken using 1.5 % agarose gels and reaction products stained with a 0.5 μg/mL solution of ethidium bromide in water prior to imaging using a Uvitech UviProchemi camera system.
Immunoblotting
After indicated treatment, cells were lysed in lysis buffer (20 mM Tris-acetate, pH 7.5, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM sodium orthovanadate, 10 mM sodium β-glycoerophosphate, 5 mM sodium pyrophosphate, 50 mM NaF, 0.1% β-mercaptoethanol, 0.2 mM PMSF and EDTA-free protease inhibitor cocktail (Roche). Aliquots of cell lysates were resolved by SDS-PAGE, transferred onto nitrocellulose membrane and probed with the appropriate antibodies. A rabbit polyclonal antibody against cleaved caspase 3 was obtained from Abcam and was used at a 1:500 dilution, and a mouse monoclonal antibody againstβ-actin was obtained from Sigma-Aldrich, and was used at a 1:20000 dilution. HRP-conjugated anti-rabbit or anti-mouse antibodies (Santa Cruz Biotechnology) were used at a 1:5000 dilution. Blots were visualised using ECL or ECL Prime+ chemiluminescence reagents (GE Healthcare Life Sciences) with X-ray development (Fuji medical film and Optimax 2010 processor).
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Data Figure S1 . Cell proliferation and cell death analysis following exposure to VG1. (A) HeLa cells were seeded on tissue culture plates as described and then treated with either DMSO only or 5 μM VG1 and imaged at indicated times. (B) HeLa cells were seeded on tissue culture plates as in A, treated with DMSO (as a control) or indicated concentrations of VG1 for 20 h and then imaged. Aberrant cell morphology indicated by white arrowheads. (C) HeLa cells were treated with either DMSO only for 48 h or 10 μM VG1 for indicated times. Cells were lysed and lysates were subjected to SDS-PAGE and Western blotting. Lysate from A2780 cis cells after 36 h cisplatin treatment was analysed in parallel as a positive control for the immunoblotting experiment. The membrane was probed for cleaved caspase 3 (upper panel) and β-actin (lower panel). Figure S2 . DNA gel electrophoresis of PCR products derived from transcripts of plasmids pmCMV-Gl (NORM), pmCMV-Gl (TER). RNA extracted from untransfected (lanes 1-3) or cells transfected with the indicated plasmid was subjected to reverse transcription and PCR as described above and the size of reaction products determined on 1.5% agarose gels by comparison to DNA molecular weight marker sets (Hyperladder I, upper panels, and Hyperladder V, lower panels (NEB)). The predicted size of the amplified DNA assuming correct splicing is 150bp, whereas unspliced product would be 803bp. Lanes 1 and 2 are controls for DNA amplification as a consequence of cross-contamination.
Comparison of NMD inhibition by NMDI1 and VG1 (see Fig. 3A )
Cells transfected with the NMD reporter constructs were treated with either DMSO or 5 μM NMDI1 or VG1 for 20 h. The amount of reporter β-globin mRNA (NORM or TER) is controlled to the amount of MUP mRNA. The data are normalised to the amount of NORM mRNA (controlled to the amount of MUP mRNA) for DMSO-treated cells. Effect of VG1 dose on NMD inhibition (see Fig. 3B )
DMSO
Cells transfected with the NMD reporter constructs were treated with VG1 at the concentrations indicated for 20 h. The amount of TER β-globin mRNA is expressed relative to the amount of NORM β-globin mRNA (both controlled to the amount of MUP mRNA) for each concentration. 
